VivoSeq
Neurology

Narcolepsy

39

Pipeline Programs↗

5

Active Trials↗

19

Companies Involved↗

Narcolepsy is a moderately active landscape with 39 programs across 19 companies. The most active players are Merck & Co., Lundbeck, Otsuka. 5 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

6/100

Mech. Concentration

29/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

1 program

Phase 1Lundbeck logo

Lundbeck

1 program

Phase 1Otsuka logo

Otsuka

1 program

Phase 1Moderna logo

Moderna

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1Eisai logo

Eisai

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

37 of 38 classified programs — the dominant modality here.

3%ALL OTHERSVaccine13%

Small molecule leads; the ring shows all 38 classified programs, each share of the total. Modality classified for 95% of 41 pipeline programs.

Analysis

Trial Status

54

clinical trials

Completed43 · 80%
Terminated4 · 7%
Recruiting3 · 6%
Not yet recruiting2 · 4%
No longer available2 · 4%

Clinical Trials

Trial Activity

54 trials

A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
Recruiting·Takeda logoTakeda·Phase 2·NCT06952699·88 enrolled
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT06961266·8 enrolled
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single- and Multiple-ascending-dose Trial Investigating Safety, Tolerability, and Pharmacokinetics of Lu AH69593 in Healthy Participants, Including Open-label Cohorts to Explore Pharmacodynamic Properties in Participants With Narcolepsy, and Food Effect in Healthy Participants
Recruiting·Lundbeck logoLundbeck·Phase 1·NCT07613710·104 enrolled
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Not yet recruiting·Eisai logoEisai·Phase 2·NCT07493265·64 enrolled
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
Not yet recruiting·NNLS Pharmaceutics·Phase 3·NCT05914194·48 enrolled
Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy
Completed·CCephalon·Phase 3·NCT00107796·140 enrolled
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02348632·645 enrolled
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT02806908·24 enrolled
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
Completed·AAlza Corporation, DE, USA·Phase 2·NCT00424931·16 enrolled
A Study to Evaluate the Safety and Efficacy of TS-091 in Patients with Narcolepsy
Completed·TTaisho Pharmaceutical Co., Ltd.·Phase 2·NCT03267303·53 enrolled
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Completed·AAlkermes, Inc.·Phase 2·NCT06555783·93 enrolled
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02221869·106 enrolled
Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
Completed·CCentre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal·N/A·NCT01394614·24 enrolled
A Study to Assess the Long-term Efficacy and Safety of AXS-12 (Reboxetine) in Subjects With Narcolepsy (ENCORE)
Completed·AAxsome Therapeutics, Inc.·Phase 3·NCT05113745·68 enrolled
Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT00066170·231 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)